Enzymatica

Enzymatica launched the campaign *Beat Every Cold Faster*, supported by consumer insights and independent research on ColdZyme.

A scientific article published in the The Journal of Physiology, confirms that ColdZyme not only alleviates cold symptoms but can also reduce the number of sick days. The article is a collaboration between the University of Kent, the Ignaz Semmelweis Institute, and Vetmeduni Vienna.

A study in *The Journal of Physiology* confirms ColdZyme reduces cold symptoms and sick days, involving University of Kent, Ignaz Semmelweis Institute, and Vetmeduni Wien.

Enzymatica produces bulk cosmetic formulations for skin care using its Penzyme technology, which partners market under their own brands.

Professor Doris Wilflingseder and her team from the Medical University of Innsbruck recently showed how ColdZyme breaks the viral infection cycle and significantly reduces the viral load in human cells infected with influenza A. In this interview she elaborates on the research and the findings.

ColdZyme has undergone extensive research, including clinical human and laboratory studies mimicking clinical settings. Studies show it protects against viruses causing cold and upper respiratory symptoms, alleviates symptoms, and shortens episode duration.

Erik Penser Bank has released an interview where analyst Maria Karlsson Osipova talks to Enzymatica's CEO Claus Egstrand about the recent Q1 interim report and upcoming events during the spring and summer.

Enzymatica’s shares were admitted for trading on Nasdaq First North Growth Market on June 15, 2015.

Enzymatica’s mouth spray launched in Turkey in fall 2022 under Sanofi’s Bisolviral brand, targeting a market of over 80 million consumers.

During the first months of the year, a large campaign was launched for ColdZyme in Sweden. Besides digital advertising and various influencer cooperations, a new TV commercial was produced. It has been broadcast on TV and in digital channel during the start of the year.

In 2025, the Board of Directors included seven members elected annually by the General Meeting. The Articles of Association require a minimum of three and a maximum of ten members, with up to ten deputies. Officers are elected at the first meeting after the Annual General Meeting.

The task of the Nomination Committee is to submit proposals prior to the Annual General Meeting for chairman and other members of the Board, as well as for fees and other remuneration for board assignments to each of the Board members. The Nomination Committee shall also submit proposals for election and remuneration of the auditor.

In 2025, the Board of Directors consisted of seven members elected for one year by the General Meeting. According to the Articles of Association, the Board must have at least three and at most ten members, with up to ten deputies. The Board convenes immediately after the Annual General Meeting.

Enzymatica’s corporate responsibility extends beyond risk management to ethical business conduct. Its Code of Conduct aligns with the UN Global Compact’s principles on human rights, labor, and environmental protection.

Enzymatica’s governance follows the Swedish Companies Act, its Articles of Association, internal policies, and Nasdaq First North Growth Market rules. Executive management and the Board of Directors serve on subsidiary boards.

Enzymatica’s origins trace to Iceland in the 1970s, where fish processors’ unusually soft hands inspired research into skin protection.

IIdeon Science Park, SE-223 70 Lund, Sweden Street address: Scheelevägen 19, Lund phone: +46 46 286 31 00, e-mail: [email protected]

The science that protects

Barrier technology protects

The company’s business name is Enzymatica AB (publ).

The company’s full name is Enzymatica AB (publ).

Enzymatica’s senior executives—including the CEO and five others—receive basic salary and benefits. The Board of Directors approves CEO remuneration, while the CEO prepares compensation for other executives.